A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C
NCT ID: NCT00922779
Last Updated: 2016-01-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
6661 participants
INTERVENTIONAL
2002-06-30
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin
NCT00087568
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).
NCT00077649
A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C
NCT00940420
A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
NCT00394277
REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
NCT00087646
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
peginterferon alfa-2a [Pegasys]
180micrograms sc weekly for 12-48 weeks
ribavirin
800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
peginterferon alfa-2a [Pegasys]
180micrograms sc weekly for 12-48 weeks
ribavirin
800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* serological evidence of chronic hepatitis C;
* detectable serum HCV-RNA;
* liver biopsy findings consistent with a diagnosis of chronic hepatitis C.
Exclusion Criteria
* co-infection with active hepatitis A or B;
* hepatocellular carcinoma;
* patients with severe cardiovascular disease whose condition may worsen due to acute anemia.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arkhangelsk, , Russia
Barnaul, , Russia
Barnaul, , Russia
Blagoveshchensk, , Russia
Cheboksary, , Russia
Chelyabinsk, , Russia
Chelyabinsk, , Russia
Chelyabinsk, , Russia
Cherepovets, , Russia
Chita, , Russia
Irkutsk, , Russia
Irkutsk, , Russia
Irkutsk, , Russia
Izhevsk, , Russia
Kazan', , Russia
Kemerovo, , Russia
Kemerovo, , Russia
Kemerovo, , Russia
Khabarovsk, , Russia
Khabarovsk, , Russia
Khabarovsk, , Russia
Kirov, , Russia
Krasnodar, , Russia
Krasnodar, , Russia
Krasnodar, , Russia
Krasnoyarsk, , Russia
Krasnoyarsk, , Russia
Lipetsk, , Russia
Makhachkala, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Nizhny Novgorod, , Russia
Novokuznetsk, , Russia
Novokuznetsk, , Russia
Novosibirsk, , Russia
Novoural'sk, , Russia
Omsk, , Russia
Orenburg, , Russia
Petropavlovsk-Kamchatskiy, , Russia
Rostov-on-Don, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Salekhard, , Russia
Samara, , Russia
Samara, , Russia
Saratov, , Russia
Saratov, , Russia
Saratov, , Russia
Sashi, , Russia
Stavropol, , Russia
Surgut, , Russia
Tomsk, , Russia
Tyumen, , Russia
Tyumen, , Russia
Tyumen, , Russia
Tyumen, , Russia
Ufa, , Russia
Ufa, , Russia
Ulan-Ude, , Russia
Vladivostok, , Russia
Vladivostok, , Russia
Volgograd, , Russia
Volgograd, , Russia
Yakutsk, , Russia
Yekaterinburg, , Russia
Yekaterinburg, , Russia
Yekaterinburg, , Russia
Yujno-sakhalinsk, , Russia
Yujno-sakhalinsk, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML16709
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.